Immunocore to present at the 2025 Jefferies Global Healthcare Conference

Rhea-AI Summary

Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, June 5, 2025, at 11:05 a.m. EDT. The presentation will be accessible through a live webcast on the 'Events & Presentations' section of Immunocore's website, with a replay available for a limited time after the event.

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference.

2024 Jefferies Global Healthcare Conference
Fireside Chat: Thursday, June 5, 2025, at 11:05 a.m. EDT

The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow Immunocore on LinkedIn: @Immunocore

Investor Relations

Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com

FAQ

When is Immunocore (IMCR) presenting at the 2025 Jefferies Healthcare Conference?

Immunocore will present at the conference on Thursday, June 5, 2025, at 11:05 a.m. EDT through a fireside chat format.

How can investors access Immunocore's (IMCR) presentation at the Jefferies Conference?

Investors can access the live webcast through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website at www.immunocore.com.

What type of medicines does Immunocore (IMCR) develop?

Immunocore develops immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune diseases.

Will there be a replay available of Immunocore's (IMCR) Jefferies Conference presentation?

Yes, a replay of the presentation will be made available for a limited time after the event on Immunocore's website.